BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

802 related articles for article (PubMed ID: 33480605)

  • 1. Expression of Immune Checkpoint Regulators, Cytotoxic T-Lymphocyte Antigen-4, and Programmed Death-Ligand 1 in Epstein-Barr Virus-associated Nasopharyngeal Carcinoma.
    Ahmed MM; Gebriel MG; Morad EA; Saber IM; Elwan A; Salah M; Fakhr AE; Shalaby AM; Alabiad MA
    Appl Immunohistochem Mol Morphol; 2021 Jul; 29(6):401-408. PubMed ID: 33480605
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Characterization of PD-L1 and PD-1 Expression and CD8+ Tumor-infiltrating Lymphocyte in Epstein-Barr Virus-associated Nasopharyngeal Carcinoma.
    Larbcharoensub N; Mahaprom K; Jiarpinitnun C; Trachu N; Tubthong N; Pattaranutaporn P; Sirachainan E; Ngamphaiboon N
    Am J Clin Oncol; 2018 Dec; 41(12):1204-1210. PubMed ID: 29672367
    [TBL] [Abstract][Full Text] [Related]  

  • 3. PD-L1 predicts poor prognosis for nasopharyngeal carcinoma irrespective of PD-1 and EBV-DNA load.
    Zhou Y; Shi D; Miao J; Wu H; Chen J; Zhou X; Hu D; Zhao C; Deng W; Xie C
    Sci Rep; 2017 Mar; 7():43627. PubMed ID: 28256540
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Prognostic Value of Programmed Cell Death-Ligand 1 Expression in Tumor-Infiltrating Lymphocytes and Viral Load in Peripheral Blood Mononuclear Cells for Epstein-Barr Virus-Positive Nasopharyngeal Carcinoma.
    Hu B; Sun M; Wang Z; Zheng Y; Cai W; Shi HH; Zhuang Y; Lin Q
    Clin Chem; 2020 Sep; 66(9):1219-1227. PubMed ID: 32870999
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Biomarkers predicting clinical outcomes in nasopharyngeal cancer patients receiving immune checkpoint inhibitors: A systematic review and meta-analysis.
    Qian X; Chen H; Tao Y
    Front Immunol; 2023; 14():1146898. PubMed ID: 37063822
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Programmed Death-Ligand 1 Expression, Microsatellite Instability, Epstein-Barr Virus, and Human Papillomavirus in Nasopharyngeal Carcinomas of Patients from the Philippines.
    Chang AMV; Chiosea SI; Altman A; Pagdanganan HA; Ma C
    Head Neck Pathol; 2017 Jun; 11(2):203-211. PubMed ID: 27807760
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Co-expression of PD-1 and PD-L1 predicts poor outcome in nasopharyngeal carcinoma.
    Zhang J; Fang W; Qin T; Yang Y; Hong S; Liang W; Ma Y; Zhao H; Huang Y; Xue C; Huang P; Hu Z; Zhao Y; Zhang L
    Med Oncol; 2015 Mar; 32(3):86. PubMed ID: 25702326
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prognostic perspectives of PD-L1 combined with tumor-infiltrating lymphocytes, Epstein-Barr virus, and microsatellite instability in gastric carcinomas.
    Choi E; Chang MS; Byeon SJ; Jin H; Jung KC; Kim H; Lee KL; Kim W; Park JH; Kim KH; Kim JS; Choi IS; Han DS; Ahn HS; Heo SC
    Diagn Pathol; 2020 Jun; 15(1):69. PubMed ID: 32498695
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The perivascular microenvironment in Epstein-Barr virus positive primary central nervous system lymphoma: The role of programmed cell death 1 and programmed cell death ligand 1.
    Sugita Y; Furuta T; Ohshima K; Komaki S; Miyoshi J; Morioka M; Abe H; Nozawa T; Fujii Y; Takahashi H; Kakita A
    Neuropathology; 2018 Apr; 38(2):125-134. PubMed ID: 29067721
    [TBL] [Abstract][Full Text] [Related]  

  • 10. EBV-driven LMP1 and IFN-γ up-regulate PD-L1 in nasopharyngeal carcinoma: Implications for oncotargeted therapy.
    Fang W; Zhang J; Hong S; Zhan J; Chen N; Qin T; Tang Y; Zhang Y; Kang S; Zhou T; Wu X; Liang W; Hu Z; Ma Y; Zhao Y; Tian Y; Yang Y; Xue C; Yan Y; Hou X; Huang P; Huang Y; Zhao H; Zhang L
    Oncotarget; 2014 Dec; 5(23):12189-202. PubMed ID: 25361008
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Immune checkpoint proteins (PD-L1 and CTLA-4) in endometrial carcinoma: prognostic role and correlation with CD4
    Khalifa R; Elsese N; El-Desouky K; Shaair H; Helal D
    J Immunoassay Immunochem; 2022 Mar; 43(2):192-212. PubMed ID: 34697997
    [TBL] [Abstract][Full Text] [Related]  

  • 12. PD-1 and PD-L1 in locoregionally advanced nasopharyngeal carcinoma: Substudy of a randomized phase III trial.
    Cao C; Wei Q; Tang X; Jia Y; Sun X; Li W; Hu Q; Chen X
    Head Neck; 2019 May; 41(5):1427-1433. PubMed ID: 30582240
    [TBL] [Abstract][Full Text] [Related]  

  • 13. PD-1 high expression predicts lower local disease control in stage IV M0 nasopharyngeal carcinoma.
    Jiang F; Yu W; Zeng F; Cheng G; Xu J; Yang S; Shui Y; Wu D; Yu XF; Wei Q
    BMC Cancer; 2019 May; 19(1):503. PubMed ID: 31138162
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Expression of immune checkpoint regulators, cytotoxic T lymphocyte antigen 4 (CTLA-4) and programmed death-ligand 1 (PD-L1), in female breast carcinomas.
    Kassardjian A; Shintaku PI; Moatamed NA
    PLoS One; 2018; 13(4):e0195958. PubMed ID: 29672601
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prognostic stratification of patients with nasopharyngeal carcinoma based on tumor immune microenvironment.
    Ono T; Azuma K; Kawahara A; Sasada T; Matsuo N; Kakuma T; Kamimura H; Maeda R; Hattori C; On K; Nagata K; Sato F; Chitose SI; Shin B; Aso T; Akiba J; Umeno H
    Head Neck; 2018 Sep; 40(9):2007-2019. PubMed ID: 29756253
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Poor prognosis in Epstein-Barr virus-negative gastric cancer with lymphoid stroma is associated with immune phenotype.
    Cho CJ; Kang HJ; Ryu YM; Park YS; Jeong HJ; Park YM; Lim H; Lee JH; Song HJ; Jung HY; Kim SY; Myung SJ
    Gastric Cancer; 2018 Nov; 21(6):925-935. PubMed ID: 29627937
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Analysis of Epstein-Barr Virus (EBV) and PD-L1 Expression in Nasopharyngeal Carcinoma Patients in a Non-Endemic Region.
    Dias JM; Santana IVV; da Silva VD; Carvalho AL; Arantes LMRB
    Int J Mol Sci; 2022 Oct; 23(19):. PubMed ID: 36233023
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Transcriptional analysis of immune genes in Epstein-Barr virus-associated gastric cancer and association with clinical outcomes.
    Sundar R; Qamra A; Tan ALK; Zhang S; Ng CCY; Teh BT; Lee J; Kim KM; Tan P
    Gastric Cancer; 2018 Nov; 21(6):1064-1070. PubMed ID: 29915957
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Epstein-Barr virus-encoded EBNA2 alters immune checkpoint PD-L1 expression by downregulating miR-34a in B-cell lymphomas.
    Anastasiadou E; Stroopinsky D; Alimperti S; Jiao AL; Pyzer AR; Cippitelli C; Pepe G; Severa M; Rosenblatt J; Etna MP; Rieger S; Kempkes B; Coccia EM; Sui SJH; Chen CS; Uccini S; Avigan D; Faggioni A; Trivedi P; Slack FJ
    Leukemia; 2019 Jan; 33(1):132-147. PubMed ID: 29946193
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Intratumoural PD-L1 expression is associated with worse survival of patients with Epstein-Barr virus-associated gastric cancer.
    Seo AN; Kang BW; Kwon OK; Park KB; Lee SS; Chung HY; Yu W; Bae HI; Jeon SW; Kang H; Kim JG
    Br J Cancer; 2017 Dec; 117(12):1753-1760. PubMed ID: 29073638
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 41.